| by product type |
- whole blood
- red cells
- granulocytes
- plasma
- platelets
- blood components
- whole blood components
- packed red cells
- leukocyte reduced red blood cells
- frozen plasma
- platelet concentrate
- blood derivatives
|
| by blood thinning agents |
- platelet aggregation inhibitor
- glycoprotein Inhibitors
- ADP Antagonists
- COX Inhibitors
- Phosphodiesterase Inhibitors
- fibrinolytics
- Tissue Plasminogen Activator (TPA)
- urokinase
- streptokinase
- anticoagulants
- Heparins
- direct thrombin inhibitors
- vitamin K antagonists
- direct factor Xa inhibitors
|
| Geographically |
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East Asia
- Rest of the World
|
Aim of the blood component is to provide right component to right patient in right quantity. Blood derivative market is the most lucrative segment and is anticipated to grow at faster rate during the forecast period due to increasing need of transfusion, and growing R&D result in development of blood derived medicines. However, anti-coagulant accounted largest share of the global blood preparation market due to launch of products, and increasing R&D activities.
North America accounted for the largest share of the market due to high patient awareness with more healthcare expenditure, and sophisticated healthcare infrastructure. However, Asia Pacific is anticipated to grow at the highest rate owing to favorable government initiatives, and large unmet opportunities from emerging markets such as China, and India.
The global blood preparation market is expected to grow at a significant growth rate during the forecast period owing to increasing prevalence of blood related diseases that results in growing demand of blood transfusion.
Additionally, launch of new anticoagulants in the market, and presence of large unmet needs also boost the global blood preparation market. However, chances of transmission of diseases, allergic reactions, and some other adverse reactions such as hypotensive transfusion reaction, post-transfusion purpura (PTP), and transfusion-associated dyspnea (TAD) can restraint the market.
According to WHO, about 5% of HIV infections are transmitted by unsafe transfusion due to unsafe donors, inadequately trained staff, irregular or inadequate supplies of materials to test, poor laboratory testing procedures, and unnecessary transfusions or absence of quality systems.
Key players in the global blood preparation market include GlaxoSmithKline plc, Baxter Healthcare Corp., Pfizer Inc., Bristol-Myers Squibb Company, Sanofi Aventis, AstraZeneca plc, and Celgene Corporation., and Leo Pharma A/S.